Executive Appointments for Next Year Including President Kim Young-ah and Vice President Kevin Sharp
John Lim, CEO of Samsung Biologics, Reappointed
Samsung Biologics and Samsung Bioepis, which have been achieving record-breaking results since their establishment, have carried out next year's personnel appointments based on the principle of performance-based evaluation.
Samsung Biologics announced on the 29th that Kevin Sharp, Head of the New Jersey Sales Office, who led the expansion of market share by securing large-scale new orders from global pharmaceutical companies, has been promoted to Vice President.
Additionally, Sungchul Yoo, Executive Director, who contributed to sales growth by achieving full operation through the efficiency of production process and schedule management at Plant 3 and stable pharmaceutical production; Inseop Song, Executive Director, who contributed to expanding management performance by improving purchasing and outsourcing processes and optimizing cost and investment expenses; and Taehee Lee, Executive Director, who contributed to securing competitiveness in the Contract Development Organization (CDO) business by developing new platform technologies and introducing automation related to research and development, were each named in the new executive roster. Executive Director Inchang Hwang was recognized for his contribution to enhancing corporate image through internal and external communication and raising brand value in the CDMO market, while Executive Director Youngseok Song was acknowledged for leading the establishment of the company's unique organizational culture.
John Rim, CEO of Samsung Biologics, has been confirmed for reappointment. Since his inauguration in December 2020, CEO Rim has achieved the highest performance with annual orders exceeding 5 trillion won since the establishment of Samsung Biologics, and is evaluated as steadily leading Samsung's new business.
A Samsung Biologics official stated, "We have boldly selected talents who have demonstrated potential and outstanding performance to drive the company's sustainable growth," adding, "We aim to secure future competitiveness and further solidify our position as a global leading company." Samsung Biologics plans to conduct company-wide organizational restructuring and position appointments following this regular executive personnel appointment.
Samsung Bioepis also selected next year's promotees with the goal of continuing growth in the global bio and pharmaceutical industry based on talents with growth potential and expertise. The newly promoted Executive Directors are Daesung Kang, Head of HR Planning Group in the HR Team; Jihun Gil, Head of Clinical Development Group in the PE Team; and Kitae Bong, Head of Culture Group in the PD Team.
Earlier, Samsung Bioepis appointed Kyungah Kim, Vice President and Head of the Development Division, as CEO and President the day before. She is the first female professional manager CEO in Samsung Group history. CEO Kim graduated with a bachelor's and master's degree in pharmacy from Seoul National University and earned a Ph.D. in toxicology from Johns Hopkins University in the United States. She is an expert in biosimilar development and joined Samsung Electronics' Advanced Institute of Technology as a senior researcher in bio new drug development in 2010. She joined Samsung Bioepis in 2015 and has played a key role across the business, including biosimilar development, process, quality, and regulatory approval.
Samsung Bioepis stated, "As the first female professional manager CEO in Samsung Group, CEO Kim is expected not only to present a growth vision to female talents and provide an opportunity to take bold challenges but also to become a role model for the women who make up more than half of Samsung Bioepis's workforce, thereby injecting new vitality into the organization."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
